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Well-differentiated/dedifferentiated (WD/DD) liposarcoma is a rare malignancy of adi-
pocyte origin (“fat cancer”). Tumors may be entirely WD, WD with a DD component, 
or rarely DD without a clear WD component. WD tumors are low grade and generally 
indolent, while tumors with a DD component are high grade and behave much more 
aggressively, with a modest potential for distant metastasis. The presence of cancer 
progenitor cells in WD/DD liposarcoma is suggested by clinical evidence and reported 
research findings. In addition, there are emerging data to support the existence of a 
naturally occurring, antigen-driven, and adaptive immune response within the tumor 
microenvironment. We hypothesize that the intratumoral immune response is directed 
against a cancer progenitor cell and that the outcome of this response impacts the 
development of WD versus DD disease. Further study will likely provide interesting 
insights into the disease biology of WD/DD liposarcoma that may be readily translated 
to other more common cancers.
Keywords: liposarcoma, dedifferentiation, tertiary lymphoid structures, ectopic lymph node, cancer stem cells, 
tumor-initiating cells
Well-differentiated/dedifferentiated (WD/DD) liposarcoma is a rare form of cancer, which origi-
nates from an adipocyte and is therefore a malignancy of fat (1, 2). Tumors most commonly occur 
in the retroperitoneum, where they can reach impressive size (mean: 30 cm) by the time of initial 
presentation (3, 4). In addition, unique to this disease, tumors can have distinct low-grade (WD) 
and high-grade (DD) areas juxtaposed next to one another. In fact, tumors may be entirely WD, WD 
with a DD component, or rarely DD without a clear WD component. The true relationship between 
the WD and DD components of tumor is unclear; however, presence of DD dramatically changes 
the disease biology and clinical outcome (1, 2, 5).
In this article, we will review available data to support the presence of cancer progenitor cells and 
an intratumoral immune response in this disease. Merging these two areas of ongoing research, we 
FiGUre 1 | (a) Photomicrograph (H&E) showing characteristic liposarcoma histology with juxtaposed well-differentiated (WD, low grade) and dedifferentiated (DD, 
high grade) areas of the same tumor. (B) Sectioned WD tumor with a probable focus of DD (white circle).
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propose a unique hypothesis that may help to elucidate disease 
biology in WD/DD liposarcoma. We believe that the immune 
response is directed against a cancer progenitor cell and that the 
outcome of this response impacts the development of WD versus 
DD disease.
Wd and dd: “a Good BrotHer  
and a Bad BrotHer”
Both WD and DD liposarcoma share a common genetic aber-
ration, amplification of chromosomal region 12q13–15 (1, 2). 
This results in up to several thousand copies of a number of 
critical genes, including MDM2 and CDK4. Amplification of 
this region and/or specific genes found in this region (e.g., 
MDM2) can be detected by fluorescence in situ hybridization 
(FISH), and this test is used to establish diagnosis of WD/DD 
liposarcoma in cases in which diagnosis cannot be made on 
histology alone.
Despite common genetic features, WD and DD liposarcoma 
can be thought of as a spectrum of disease with clear differ-
ences between WD and DD (5). By histology, WD liposarcoma 
(low grade) consists of adipocytes of varying size, separated by 
fibrous bands with hyperchromatic cells (HCs); in contrast, in 
DD liposarcoma (high grade), the adipocytic areas are replaced 
by cellular areas, frequently with mitotic figures (Figure 1A). 
Macroscopically, WD tumors contain mostly fat, whereas DD 
areas of tumor are more dense, with a white, “fleshy,” and/or 
vascularized appearance (Figure  1B). These differences can 
be seen on cross-sectional imaging, which can suggest the 
presence of DD (often seen arising from or adjacent to WD 
areas of tumor); however, the final diagnosis of DD is made by 
histology.
Tumors that have a DD component are clearly more aggres-
sive, and patients overall do worse. WD tumors are generally 
indolent and do not have the potential for distant metastasis. In 
contrast, tumors with DD frequently invade into adjacent organs 
and structures and up to 20–30% of cases metastasize, most com-
monly to the lungs (6). After surgery, the rates of locoregional 
recurrence are higher, and the time of recurrence is faster in DD 
versus WD tumors (7, 8). Interestingly, although response to 
radiation therapy and systemic therapy is overall poor for both, 
for cytotoxic chemotherapy (e.g., doxorubicin), DD has a slightly 
better response rate compared to WD (12 versus 0%) (9).
CanCer proGenitor CeLLs in Wd/dd 
LiposarCoMa
Cancer progenitor cells or “stem cells” have been reported and 
characterized in a number of human solid tumors (10–13). 
This unique subpopulation of cells is defined by the ability to 
self-renew and the capacity to differentiate into other cell types 
(pluripotency). Cancer progenitor cells are tumorigenic and, 
even in small numbers, can form an entire tumor. Clinically, 
these cells are thought to be more resistant to therapy compared 
to non-progenitor cells. As a result, cancer progenitor cells may 
play a fundamental role not only in tumorigenesis but also in 
recurrence and even distant metastasis. Specific cell surface and 
functional markers have been identified, which are suggestive of 
cancer progenitor cells.
There is some clinical evidence to suggest the presence of a 
cancer progenitor cell in WD/DD liposarcoma. Evans et al. was 
one of the first to report the observation of heterologous differen-
tiation in this disease (14). By histology, some tumors (~5–10%) 
may exhibit features consistent with lineage differentiation to 
bone, muscle, blood vessel, or other tissue, suggesting the exist-
ence of a cell within the tumor with pluripotency (15, 16). WD/
DD liposarcoma has also been reported to express CD117 or 
c-kit, also known as “stem cell factor” (17, 18). In addition, some 
tumors have high expression of CD34, another established stem 
cell marker (19). Riddle et al. even described a case report of a 
patient with a CD117 and CD34 double positive, but MDM2-
amplified, liposarcoma “masquerading” as a gastrointestinal 
stromal tumor (20).
Several research investigators have also directly explored the 
presence of cancer progenitor cells in WD/DD liposarcoma. 
Stratford et  al. used immunohistochemistry (IHC) to show 
FiGUre 2 | (a) Intratumoral tertiary lymphoid structure (TLS, green outline) found in WD liposarcoma. (B) By immunohistochemistry, TLS contain a dense population 
of CD4 T cells (brown). (C) DC-LAMP-positive dendritic cells are found adjacent to CD4 T cells (green boxes).
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that all (six out of six) cases of WD/DD liposarcoma expressed 
high levels of aldefluor, a functional stem cell marker (21). 
Interestingly, all the cases were also negative for CD133, a dif-
ferent stem cell marker. Using a human liposarcoma cell line 
(SW872)-based xenograft mouse model, the authors were able 
to identify a progenitor cell subpopulation that could form 
de novo tumors with as few as 100 cells. Smith et al. studied a 
xenograft mouse model established by implanting human WD/
DD liposarcoma tumors obtained from surgery. Tumors that 
engrafted successfully appeared to have a gene signature with a 
“progenitor-like phenotype” (22).
It is important to note that the presence of cancer progenitor 
cells seems to be more pronounced in DD than WD liposarcoma. 
Heterologous differentiation is mostly seen in DD. CD117 expres-
sion was seen in 30% of DD cases studied by Tayal et al. versus 
none in WD (17). In liposarcoma cell lines, the majority of those 
with evidence for stem cell potential are DD or derived from 
“poorly differentiated” tumors (23). In xenograft mouse models, 
both Smith et al. and Peng et al. have independently confirmed 
that DD but not WD tumors have the potential to engraft success-
fully (22, 24). As a likely explanation, the highest percentage of 
CD34-positive stem cells is seen in DD tumors compared to WD 
and normal fat (25).
tHe intratUMoraL iMMUne 
response in Wd/dd LiposarCoMa
In the late 1990s, Argani et  al. and Kraus et  al. originally 
described an “inflammatory” variant of WD liposarcoma, 
based on the presence of a prominent immune infiltrate (26, 
27). Recently, our group has reported a more detailed char-
acterization of the intratumoral immune response that occurs 
naturally in both WD and DD liposarcoma (28, 29). One 
noteworthy observation is the presence of organized aggregates 
of immune cells within the tumor microenvironment, known 
as tertiary lymphoid structures (TLS) (Figure  2). Our work 
demonstrated that TLS contain mature dendritic cells situated 
adjacent to CD4 helper T cells, a feature suggestive of antigen 
presentation. TLS also contain B cells and, in fact, can have 
a clear germinal center. CD8 cytotoxic T cells are also found; 
however, these are typically scattered in the areas of tumor 
outside of TLS. Taken together, our findings strongly suggest 
that there is an antigen-driven, adaptive immune response in 
WD/DD liposarcoma. The key question is: what are the tumor 
antigen(s) that are being targeted by the intratumoral immune 
response in WD/DD liposarcoma?
stroMaL HyperCHroMatiC CeLLs: 
tHe “MissinG LinK”?
Within the tumor stroma of WD liposarcoma, there exists an 
atypical, spindle-shaped cell with a hyperchromatic nucleus. 
These HCs are seen often enough by routine histology that 
they are used by clinical pathologists as part of the criteria for 
disease diagnosis (30, 31). In support of this, by FISH, HCs 
demonstrate high, if not the highest levels of amplification, 
confirming their identity as tumor cells (32). However, the 
significance of HCs in WD/DD liposarcoma has never been 
studied to our knowledge.
Our group has preliminary data to suggest that HCs 
express both CD34 and MHC Class I (Figure  3). CD34 has 
been reported to be a marker for adipocyte stem cells (ASCs) 
by several investigators. In addition to liposarcoma (19, 20, 
25), CD34-positive cells with stem cell gene expression and 
functional characteristics have also been reported in normal 
fat and benign lipomas (33–36). Although further studies are 
needed, our preliminary data would suggest that HCs may be 
ASCs in WD/DD liposarcoma. MHC Class I is a cell surface 
molecule involved in antigen display. Although tumor cells 
can downregulate MHC Class I to evade immune detection, its 
expression on HCs suggests that HC antigen can be recognized 
by the adaptive immune response.
HypotHesis and FUrtHer  
areas oF stUdy
We hypothesize that, in WD/DD liposarcoma, the intratumoral 
immune response (TLS) is directed against a candidate cancer pro-
genitor cell (HC). We further hypothesize that differential immune 
FiGUre 4 | Hypothesis: (a) in low-grade, well-differentiated (WD) disease, MHC Class I-expressing stromal hyperchromatic cells (HCs) differentiate along an 
adipocytic lineage and undergo slow proliferation. Some HCs are recognized by dendritic cells (DC), which form an intratumoral tertiary lymphoid structure (TLS);  
(B) however, through yet undefined mechanisms, HCs are able to evade the immune response and rapidly proliferate, resulting in high-grade, dedifferentiated (DD) 
disease. Alternatively, TLS may be an “immune-privileged” site that directly supports the growth of HCs (right, red box).
FiGUre 3 | (a) Stromal hyperchromatic cells (HCs) in WD/DD liposarcoma (red boxes). HCs express MHC Class I (brown, insets). (B) HCs also express high levels 
of CD34 (solid arrow) and have 12q13–15 amplification (dotted arrow; FISH courtesy of KL Bill). *HCs were isolated from fresh tumor tissue after excluding immune 
cells and endothelial cells and gating on the population with the highest side scatter (SSC-A = internal complexity) and Class I (HLA-ABC).
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responses against this unique tumor cell ultimately leads to the 
development of WD versus DD disease (Figure 4). Initially, HCs 
undergo a low level of proliferation that results in a WD tumor. 
On a cellular level, HCs (CD34-positive, likely ASC) differentiate 
along an adipocytic lineage, and the histology is low grade. In at 
least some HCs, antigen is presented on the cell surface (via MHC 
Class I) and recognized by the adaptive immune cells, which, in 
response, form an intratumoral TLS. An attempt is made by the 
immune cells to eliminate HCs; however, this is unsuccessful. HCs 
are able to evade the adaptive immune response or alternatively, 
TLS may even become an “immune-privileged” site in direct sup-
port of HCs. The net result is much more rapid proliferation of 
HCs, forming the cellular areas characteristic of high-grade disease 
(=DD). The tumor microenvironment(s) in WD/DD liposarcoma 
FiGUre 6 | potential natural progression from a formed tLs (1, green outline) to disrupted tLs with an adjacent, developing cellular/dd area of 
tumor (2) to a locally-invasive, cellular/dd area (red outline) without tLs (3). See also insets.
FiGUre 5 | Hyperchromatic and MdM2-positive tumor cells (brown) 
are found within and just adjacent to tLs (green outline).
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may therefore represent a dynamic form of cancer immunoediting 
(“elimination, equilibrium, and escape”), similar to that which 
has been proposed by others (37–39). In WD/DD liposarcoma, 
immunoediting occurs across the spectrum of low- to high-grade 
disease and is directed against a cancer progenitor cell.
Tertiary lymphoid structures have recently been suggested to 
serve as a microniche to promote the growth of cancer progenitor 
cells in hepatocellular carcinoma (HCC) (40). In the precancer-
ous liver of a genetically engineered mouse model of HCC, TLS 
form around a progenitor cell, which proliferates and ultimately 
“overtakes” the TLS, resulting in frank HCC. The concept of 
progenitor cells existing in an immune-privileged niche has been 
reported in other cancers as well (41, 42). Re-examination of WD/
DD liposarcoma demonstrates that, in fact, hyperchromatic and 
strongly MDM2-positive cells are found within TLS (Figure 5). 
Moreover, we have observed unique patterns of TLS organization 
that could be interpreted as a progressive “overtaking” of TLS by a 
developing cellular/DD area of tumor (Figure 6). Coincidentally, 
although TLS have been reported in a number of other cancers 
and shown to be associated with better prognosis, the opposite is 
true in both HCC and WD/DD liposarcoma (29, 40).
Further study to support or refute our hypothesis is clearly 
needed. From an immunology standpoint, this should first occur 
broadly, looking at the differences in the immune response across 
the spectrum of disease, with tumors that are entirely WD, WD 
with a DD component, and DD without a WD component. 
If our hypothesis is true, the overall immune bias (cellular 
composition, function, and cytokine production) should differ 
vastly from WD to DD, even regionally within the same tumor. 
From a tumor standpoint, HCs should be isolated and further 
characterized. If HCs are the targets of TLS via antigen display 
on MHC Class I, it is unclear why they are selectively targeted. 
CD34-positive ASCs have been reported to undergo proliferation 
in benign lipomas (35, 36). In WD liposarcoma, it is possible that 
in some proliferating HCs low levels of mutated antigen(s) arise, 
which are then recognized by the adaptive immune cells. There 
should also be focused investigation into the initial cell-to-cell 
interaction between HCs and the dendritic cell precursors that 
will result in antigen presentation to naive T and B cells within 
TLS. Importantly, is there an ultimate failure of HC-antigen 
presentation or is the deficiency at the downstream effector 
cells targeting HCs? In support of the latter, we have previously 
reported that in WD/DD liposarcoma, intratumoral CD8 T cells, 
which are typically outside of TLS, have high expression of PD-1, 
an immune checkpoint molecule and natural “stop signal” for 
these effector cells (29). Alternatively, do the HCs recruit suppres-
sive immune cell types or do they themselves directly suppress 
the mounting immune response? In support of the former, we 
recently described a case report of multicystic DD liposarcoma 
with a prominent monocytic immune cell subpopulation that is 
likely comprised of myeloid-derived suppressor cells and tumor-
associated macrophages (43).
In WD/DD liposarcoma, further study of the intratumoral 
immune response against a candidate cancer progenitor cell will 
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likely provide meaningful insights into the biology of this disease. 
However, one important caveat is that the clonal origin and true 
relationship between WD and DD is still unknown. Nonetheless, 
this work may also result in identification of clinical biomark-
ers for disease progression and novel targets for therapy (e.g., 
immunotherapy) (44). There may be a specific gene or cytokine 
signature in TLS that is indicative of pure WD versus early (sub-
clinical) development of DD disease. One interesting observation 
is that DD occurs much less frequently in tumors that arise in the 
extremity and trunk compared to the retroperitoneum (15, 45, 46). 
Could this be driven or, at least, influenced by the intratumoral 
immune response (e.g., frequency or type of TLS formed)? In 
terms of therapy, appropriate manipulation of TLS may potentially 
prevent DD and maintain WD, which would improve prognosis 
and is overall a more clinically manageable disease.
Finally, further hypothesis-driven study in WD/DD liposar-
coma may uncover findings that can be readily translated into 
other, more common cancers. There is a plethora of literature 
about cancer progenitor cells in a variety of cancers; there is now 
also an increasing body of work characterizing TLS in non-small 
cell lung cancer, melanoma, colorectal cancer, and others (47). 
To our knowledge, the true “targets” of the adaptive immune 
response represented by TLS in these cancers is still yet undefined. 
Therefore, although rare, with its unique disease characteristics, 
WD/DD liposarcoma may be an ideal “cancer model” to study 
the tumor–immune microenvironment and, specifically, from 
the standpoint of the immune response against cancer progenitor 
cells.
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